 Home > Active Ingredient News > Drugs Articles > $660 million! Gilead and EVOQ agree on immunotherapy

$660 million! Gilead and EVOQ agree on immunotherapy

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

different types soda

dendritic cells location

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On January 3, EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc.
, making it possible for EVOQ to obtain up to 6.
585 Billions of dollars in earnings
.
The two companies will collaborate to advance preclinical development, with Gilead responsible for clinical development and commercialization
.

Making it possible for the EVOQ to obtain up to 6.
585 Billions of dollars in earnings
.
Gilead will be responsible for clinical development and commercialization
.

"Despite significant progress over the past two decades, there is still a significant unmet need
for people living with inflammatory and autoimmune diseases.
" Executive Vice President, Gilead Research Dr.
Flavius Martin said, "We are delighted to partner with EVOQ [to address] the needs
of people living with these conditions.
”

Executive Vice President, Gilead Research Dr.
Flavius Martin said

EVOQ's technology is designed to enable lymphatic-targeted delivery of disease-specific antigens that have been optimized to deliver antigens to restore immune tolerance
.
The technology has the potential to change the paradigm in the treatment of autoimmune diseases
.
according to EVOQ, which works mainly by activating dendritic cells, which are abundant in
the human lymphatic system.
Dendritic cells trigger different types of effector T cells, to coordinate immune responses
against immune tolerance or immune activation.

Depending on the terms of the agreement, EVOQ may receive a total of up to 6.
585 $100 million in advance payments, option exercises and milestone payments for all items, and tiered royalties
on product sales.
Gilead will have the option to exclusively license EVOQ's NanoDisc technology in pursuit of RA and product candidates for lupus indications
.

Original link: _mstmutation="1" _msthash="220729" _msttexthash="6888128">

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Methyl-L-alanine3913-67-5

CAS No.: 3913-67-5

Industrial Grade

$1-1.04/KG FOB

High Purity 99% PEG MGF CAS 108174-48-7 Customized Peptides from China OUDA

CAS No.: 108174-48-7

Pharmacy Grade

$2-2.6/G FOB

Wholesales Purity 99 Peptides Powder Sema Tirz Retatrutide 5mg/10mg/15mg to Door From China

CAS No.: 2023788-19-2

Pharmacy Grade

$150-180/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.